RESUMO
Vital for human consumption, water is a scarce resource, particularly in the arid environments of Patagonia. In this study we analysed local perspectives and the use of different water sources, based on two case studies in rural communities of Mapuche and Creole ancestry inhabiting extra-Andean Patagonia in Chubut, Argentina. Water quality was evaluated using an ethnolimnological, interdisciplinary approach, taking into account local perspectives and scientific contributions. In addition, we analysed appropriation strategies, management and local organoleptic characteristics. The work was based on semi-structured interviews, tours guided by informants, and physicochemical and microbiological analysis of water sources. It was found that 92% of local inhabitants mainly used superficial and subterranean sources of water for consumption, among which stood out: river, streams, springs, wells, and boreholes. Differences were observed between local and scientific perspectives in terms of water quality (chemical and microbiological). Most water sources used by inhabitants presented water of deficient quality for human consumption (61%), whereas locals considered the water to be fresh, delicious, and transparent. Nevertheless, some points of agreement were found in terms of organoleptic characteristics (e.g., odour, colour) and physicochemical parameters in certain water sources. In general, locals do not recognise the deterioration of their water supply, but the importance of organoleptic characteristics in local perception should be highlighted. These aspects speak of a need to promote opportunities for dialogue, and implement effective health measures, taking local perspectives into account.
Assuntos
Qualidade da Água , Abastecimento de Água , Argentina , Odorantes , RiosRESUMO
OBJETIVO: Este estudio pretende evaluar la sobrevida global en los pacientes con carcinoma diferenciado de tiroides localmente avanzado yodo refractario. MÉTODO: Son 8 casos tratados con inhibidores de tirosina quinasa (Sorafenib) en el período comprendido entre 2014-2017. Las variables estudiadas fueron: Epidemiológicas, laboratorios tiroideos, histología, tratamiento, supervivencia posterior al tratamiento. Se tomó como significativo una P<0,05. RESULTADOS: Edad media entre los pacientes fue 51 años ± 22,1 años, el sexo prevaleciente fue femenino (75 %). El lugar de procedencia más incidente fue Estado Miranda (50 %). Los valores de laboratorio al momento del diagnóstico fueron tiroglobulina (290,2 ± 250,7), la TSH (11,3 ± 13,9) y la antitiroglobulina solo fue positiva en un paciente (87,5 %). La T predominante fue T3 (50 %), la N que prevaleció fue N1B (62 %) y M1 (62,5 %). El estadio predominante fue IVC (50 %). El grupo histológico predominante fue papilar (62,5 %). Se les realizó tiroidectomía total con vaciamiento bilateral al 75 % de los pacientes. Posteriormente recibieron 131I, para los cuales se obtuvieron una dosis media de 227,5 mCi con desviación de estándar: 188,1 mCi. La mayoría recibió radioterapia externa a región cervical (87,50 %). La sobrevida global 3 años posteriores al tratamiento fue 87,5 %. CONCLUSIONES. El control de la enfermedad a largo plazo en estos pacientes avanzados puede obtenerse con Sorafenib. En nuestro estudio evidenciamos que es un fármaco adecuado para controlar la enfermedad en pacientes con cáncer de tiroides yodo refractarios.(AU)
OBJECTIVE: This study aimed evaluates overall survival in patients with locally advanced thyroid iodine refractory differentiated carcinoma. METHOD: 8 cases treated with inhibitors of tyrosine kinase (Sorafenib) in the period 2014-2017. The variables studied were: epidemiological, laboratory thyroid histology, treatment, post-treatment survival. P was taken as meaningful < 0.05. RESULTS: Mean age among patients was 51 years ± 22.1 year, prevailing sex female (75 %). Place of origin more incident was Miranda State (50 %). At the time of the diagnostic laboratory values were thyroglobulin (290.2 ± 250.7), TSH (3 ± 13.9 11) and the single antithyroglobulin was positive in one patient (87.5 %). The predominant T was T3 (50 %), the N that prevailed was N1B (62 %) and M1 (62.5 %). The predominant stadium was IVC (50 %). The predominant histological group was papillary (62.5 %). The predominant stadium was IVC (50 %). The predominant histological group was papillary (62.5 %). He was performed in total thyroidectomy with bilateral clearing to 75 % of patients. Subsequently received 131I, for which an average dose of 227.5 mCi with standard deviation were obtained: 188.1 mCi. Most received radiotherapy external cervical region (87.50 %). Global survival 3 years after treatment was 87.5 %. CONCLUSIONS: The control of disease in long run in these advanced patients can get with Sorafenib. In our study we showed that it is a suitable drug to control the disease in patients with cancer of thyroid iodine refractory. (AU)
Assuntos
Humanos , Feminino , Adulto , Tireoidectomia , Tirosina/administração & dosagem , Neoplasias da Glândula Tireoide/fisiopatologia , Inibidores de Proteínas Quinases , Metástase Neoplásica , Epidemiologia , Compostos Radiofarmacêuticos , Tratamento FarmacológicoRESUMO
The relationship between 15(S)-HETE and 13(S)-HODE from different human tumor cells exposed to n-6 and n-3 essential fatty acids (EFAs) and E-cadherin expression was studied. Colon cancer cells (HRT-18) exposed to gamma linoleic acid (18:3n-6, GLA) and eicosapentaenoic (20:5n-3, EPA) (50microM) showed an increased expression of E-cadherin. Breast cancer (MCF-7) exposed to EPA showed an increment whereas GLA had no effect on E-cadherin expression. No expression of E-cadherin was observed for urothelial cancer (T-24) after GLA or EPA treatment. Significant levels of 15(S)-HETE and 13(S)-HODE were detected after GLA or EPA treatment for all tumor lines. E-cadherin expression was inversely proportional to the 13(S)-HODE:15(S)-HETE ratio when cells were pretreated with GLA or EPA. Nevertheless, the liberation of these metabolites seems to be independent of the E-cadherin expression. The increase in the13(S)-HODE:15(S)-HETE correlates to a decrease in the expression of E-cadherin. Both factors may play a role in metastasis development.
Assuntos
Neoplasias da Mama/metabolismo , Caderinas/metabolismo , Neoplasias do Colo/metabolismo , Ácidos Hidroxieicosatetraenoicos/biossíntese , Ácidos Linoleicos/biossíntese , Neoplasias da Bexiga Urinária/metabolismo , Ácido Araquidônico/fisiologia , Neoplasias da Mama/patologia , Diferenciação Celular , Neoplasias do Colo/patologia , Feminino , Humanos , Imuno-Histoquímica , Ácido Linoleico/fisiologia , Metástase Neoplásica , Células Tumorais Cultivadas , Neoplasias da Bexiga Urinária/patologia , Urotélio/crescimento & desenvolvimentoRESUMO
Involvement of arachidonic acid cyclooxygenase (COX) and lipoxygenase (LOX) metabolites in platelet aggregation and coagulation induced by two varieties of cancer cells of murine transplantable tumors was studied. A lung alveolar carcinoma (LAC) and a fibrosarcoma (FS), induced platelet aggregation and plasma coagulation (P<0.05). Pretreatment of both tumor lines with a COX inhibitor did not block the tumor cell induced platelet aggregation (TCIPA). COX [12(S)-HTT] and LOX [12(S)-HETE], metabolites of washed platelets (WP), alone or co-incubated with LAC or FS cells, were analyzed. We observed higher 12(S)-HETE release with respect to 12(S)HHT when WP were co-incubated with LAC cells. With both neoplastic cell (NC) lines prothrombin time (PT) was shortened. Pretreatment of NC with iodoacetic acid, soybean trypsin inhibitor or Factor X-deficient plasma increased the PT. These results indicate that AA metabolites play a role on the procoagulation and platelet aggregation induced by mesenchymal and epithelial murine cancers.